TA 270

Drug Profile

TA 270

Alternative Names: TA-270

Latest Information Update: 07 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dainippon Ink & Chemicals
  • Developer Mariposa Health Limited
  • Class Antiallergics; Antiasthmatics; Quinolones
  • Mechanism of Action 5-lipoxygenase inhibitors; Antioxidants; Free radical scavengers; Immunosuppressants; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic obstructive pulmonary disease

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 07 Jan 2016 Mariposa Health plans a phase II trial for Allergic rhinitis (Inhalation) (Mariposa Health website, January 2016)
  • 30 Sep 2015 TA 270 is available for licensing as of 12 Dec 2015. www.mariposahealth.com.au
  • 30 Sep 2015 Mariposa Health plans a phase II trial for Chronic obstructive pulmonary disease in USA, European Union and Australia (Inhalation) (Mariposa Health Form 10-Q, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top